农业百科

Bayer has received another approval in China for its HER2 inhibitor sevabertinib. The National Medical Products Administration (NMPA) has authorized its use in adults with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating HER2 mutations. What is new is primarily the line of therapy: Sevabertinib can now also be used in previously untreated patients.

Why it matters: T-cell engagers have already shown success in blood cancers, but extending the approach to solid tumors remains challenging. T-Therapeutics is developing a different type of bispecific therapy designed to recognize proteins that conventional antibody-based drugs cannot easily reach.

The Series A was co-led by Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with additional support from Cancer Research Horizons and the University of Oxford.

Foto: Billy R Wiseman / USDA Pesquisadores identificaram dois genes envolvidos na regeneração do intestino médio da laga…

Foto: Wenderson Araujo / CNA Plantas de arroz submetidas ao estresse salino liberam compostos orgânicos voláteis capazes…

doi 10.3390/jof12110842 Pesquisadores da Universidade Agrícola de Nanjing, na China, caracterizaram uma linhagem de Tric…

Luiz Fernando Naso assumiu o cargo de CEO da Superbac Biotechnology Solutions. O executivo passa a comandar a companhia …

Foto: David Cappaert / Bugwood Cruzamentos entre indivíduos aparentados reduziram a capacidade reprodutiva e a sobr…

A PI AgSciences anunciou Jonas Cuzzi como novo Country Head no Brasil. O executivo assumiu o cargo após atuar como diret…